Content
05/31/2024
Cambridge, MA USA
Brixton Biosciences
completed $33 million Series B Round funding. Investors include
Schooner Capital (lead), SV Health Investors, Sparta Group, Pritzker Vlock Capital Management, Excelestar Ventures, Catalyst Health Ventures.
About
Brixton Biosciences is a clinical-stage life sciences company developing novel therapies for chronic and acute pain.
Startup
Sector:
Biotech
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
